4D Molecular Therapeutics, an Emeryville, Calif.-based gene therapy company, closed a $90m Series B financing.
The round was led by Viking Global Investors, with participation from ArrowMark Partners, Janus Henderson Investors, The Biotechnology Value Fund, MiraeAsset Financial Group, Pappas Capital & Chiesi Ventures, Pfizer Ventures, Perceptive Advisors, Ridgeback Capital Investments, CureDuchenne Ventures and Berkeley Catalyst Fund. In conjunction with the financing, Tony Yao of ArrowMark Partners has joined the 4DMT Board of Directors.
The company intends to use the proceeds to advance its proprietary Therapeutic Vector Evolution platform and pipeline of next-generation AAV gene therapeutics. Its lead intravitreally-delivered AAV gene therapy asset for choroideremia is expected to enter clinical trials in 2019.
Led by David Kirn, chairman and chief executive officer, 4DMT focuses on the discovery and development of targeted, customized and proprietary next-generation AAV gene therapy products for use in patients with severe genetic diseases with high unmet medical need.
The company’s Therapeutic Vector Evolution platform deploys over 100 million unique AAV variants from over 35 unique and proprietary 4DMT AAV libraries with extensive diversity. After defining the Target Product Profile, and the associated Target Vector Profile, 4DMT then applies proprietary methods to identify lead vectors from within our AAV libraries. The result is a customized, novel, and proprietary pharmaceutical-grade product uniquely designed for targeted therapeutic gene delivery and efficacy in humans.